| Literature DB >> 32271849 |
Jens C Kubitz1, Leonie Schulte-Uentrop1, Christian Zoellner1, Melanie Lemke2, Aurelie Messner-Schmitt1, Daniel Kalbacher3, Björn Sill4, Hermann Reichenspurner4, Benedikt Koell4, Evaldas Girdauskas4.
Abstract
Protocols for "Enhanced recovery after surgery (ERAS)" are on the rise in different surgical disciplines and represent one of the most important recent advancements in perioperative medical care. In cardiac surgery, only few ERAS protocols have been described in the past. At University Heart Center Hamburg, Germany, we invented an ERAS protocol for patients undergoing minimally invasive cardiac valve surgery. In this retrospective single center study, we aimed to describe the implementation of our ERAS program and to evaluate the results of the first 50 consecutive patients. Our ERAS protocol was developed according to a modified Kern cycle by an expert group, literature search, protocol creation and pilot implementation in the clinical practice. Data of the first 50 consecutive patients undergoing minimally invasive cardiac valve surgery were analysed retrospectively. The key features of our multidisciplinary ERAS protocol are physiotherapeutic prehabilitation, minimally invasive valve surgery techniques, modified cardiopulmonary bypass management, fast-track anaesthesia with on- table extubation and early mobilisation. A total of 50 consecutive patients (mean age of 51.9±11.9 years, mean STS score of 0.6±0.3) underwent minimally-invasive mitral or aortic valve surgery. The adherence to the ERAS protocol was high and neither protocol related complications nor in-hospital mortality occurred. 12% of the patients developed postoperative atrial fibrillation, postoperative delirium emerged in two patients and reintubation was required in one patient. Intensive care unit stay was 14.0±7.4 hours and total hospital stay 6.2±2.9 days. Our ERAS protocol is feasible and safe in minimally-invasive cardiac surgery setting and has a clear potential to improve patients outcome.Entities:
Year: 2020 PMID: 32271849 PMCID: PMC7145109 DOI: 10.1371/journal.pone.0231378
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Key features of the ERAS program (in accordance with the recommendations of the Enhanced Recovery after Surgery Society®).
Intraoperative and postoperative management.
Values are presented as numbers (%) or as mean ± SD. CPB- cardiopulmonary bypass; ICU- intensive care unit; OR- operating room; PACU- post-anesthesia care unit.
| Surgical variables | Study cohort (n = 50) |
|---|---|
| Mitral valve surgery | 23 (46%) |
| - mitral valve repair | 22 (44%) |
| - mitral valve replacement | 1 (2%) |
| Aortic valve surgery | 26 (52%) |
| - aortic valve repair | 12 (24%) |
| - aortic valve replacement | 11 (22%) |
| - concomitant aortic root surgery | 8 (16%) |
| - fibroelastoma removal | 3 (6%) |
| Isolated ascending aorta replacement | 1 (2%) |
| CPB time (min) | 137.8 ± 47.9 |
| Aortic cross-clamp (min) | 83.1 ± 31.4 |
| Total surgery time (min) | 184.4 ± 53.2 |
| Extubation in the OR | 48 (96%) |
| PACU stay (min) | 205.7 ± 69.3 |
| ICU discharge (hours) | 14.0 ± 7.4 |
| Total days in hospital (days) | 6.2 ± 2.9 |
| In-hospital mortality | 0 (%) |
Demographics and baseline variables.
Values are presented as numbers (proportion) or as mean ± SD. CAD- coronary artery disease, NYHA–New York Heart Association functional class.
| Variable | Study cohort (n = 50) |
|---|---|
| Mean age (years) | 51.9 ± 11.9 |
| Sex (male / female) | 38 / 12 |
| Body Mass Index (kg/m2) | 26.1 ± 3.1 |
| Surgical Risk scores: | |
| - STS score | 0.6 ± 0.3 |
| - Log. EuroScore | 1.7 ± 0.9 |
| Comorbidities | |
| - NYHA class | 2.0 ± 0.8 |
| - Hypertension | 24 (48%) |
| - CAD | 5 (10%) |
| - Atrial fibrillation | 7 (14%) |
| - Smoking | 6 (12%) |
| - Diabetes | 2 (4%) |
Postoperative medication in the PACU.
| Medication | Study cohort (n = 50) | |
|---|---|---|
| Number of patients | Mean dose | |
| Norepinephrine | 9 | 0.027 ± 0.013 μg.kg-1.min-1 |
| Piritramid | 37 | 11.8 ± 6,0 mg |
| Oxycodon | 5 | 6.0 ± 2.2 mg |
| Piritramid and Oxycodon | 4 | |
| Ondansetron | 9 | 4.0 mg |
Postoperative complications.
* requiring pacemaker implantation.
| Event | Study cohort (n = 50) | Comment |
|---|---|---|
| Cardiovascular: | ||
| - Atrial Fibrillation | 6 (12%) | After AV replacement |
| - Permanent AV-Block III°* | 2 (4%) | 2 bleeding events / 1 redo |
| - Redo surgery | 3 (6%) | due to valvular problems |
| Pulmonary: | ||
| - Reintubation | 1 (2%) | generalized seizure |
| - Nosocomial infection | 2 (4%) | |
| Neurological: | ||
| - Stroke | 1 (2%) | 1 PACU |
| - Delirium | 2 (4%) | 1 PACU, 1 general ward |
| General: | ||
| - Bacteriuria | 3 (6%) | |
| - RBC transfusion | 12 (24%) |
Incidence of pain and PONV in the early vs. late phase of ERAS program.
| Variable | Early phase (n = 20) | Late phase (n = 30) | p value |
|---|---|---|---|
| 6 (30%) | 2 (7%) | 0.03 | |
| 7 (35%) | 2 (7%) | 0.02 |